Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Shigeru Kageyama"'
Autor:
Chieko Kurihara, Hideo Kusuoka, Shunsuke Ono, Naoko Kakee, Kazuyuki Saito, Kenji Takehara, Kiyokazu Tsujide, Yuzo Nabeoka, Takuya Sakuhiro, Hiroshi Aoki, Noriko Morishita, Chieko Suzuki, Shigeo Kachi, Emiko Kondo, Yukiko Komori, Tetsu Isobe, Shigeru Kageyama, Hiroshi Watanabe
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e84998 (2014)
IntroductionInternational norms and ethical standards have suggested that compensation for research-related injury should be provided to injured research volunteers. However, statistical data of incidence of compensation claims and the rate of awardi
Externí odkaz:
https://doaj.org/article/9d6898591b834b34bab7c245b383573c
Autor:
Nobuhiro Ooba, Tsugumichi Sato, Akira Wakana, Takao Orii, Masaki Kitamura, Akira Kokan, Hideaki Kurata, Yoshihiro Shimodozono, Kenichi Matsui, Hiroshi Yoshida, Takuhiro Yamaguchi, Shigeru Kageyama, Kiyoshi Kubota
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e96919 (2014)
PURPOSE: To assess the association between statins and diverse adverse events in Japanese population. METHODS: New users of statin who started statin after 6-month period of non-use were identified in 68 hospitals between January 2008 and July 2010.
Externí odkaz:
https://doaj.org/article/cc32605692a6492d86746a8fd604cfd6
Autor:
Keitaro Yokoyama, Akio Nakashima, Mitsuyoshi Urashima, Hiroaki Suga, Takeshi Mimura, Yasuo Kimura, Yasushi Kanazawa, Tamotsu Yokota, Masaya Sakamoto, Sho Ishizawa, Rimei Nishimura, Hideaki Kurata, Yudo Tanno, Katsuyoshi Tojo, Shigeru Kageyama, Ichiro Ohkido, Kazunori Utsunomiya, Tatsuo Hosoya
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e51171 (2012)
We aimed to examine associations among serum 25-hydroxyvitamin D (25OHD) levels, 1,25-dihyroxyvitamin D (1,25OHD) levels, vitamin D receptor (VDR) polymorphisms, and renal function based on estimated glomerular filtration rate (eGFR) in patients with
Externí odkaz:
https://doaj.org/article/f6c8c0aef5c649a6828010a50cfce63e
Autor:
Masato Odawara, Fumiko Ueki, Yasuhiko Iwamoto, Ryuzo Kawamori, Shigeru Kageyama, Naoko Tajima, Nigishi Hotta, Yasuhide Yodo
Publikováno v:
Diabetology International. 8:286-295
In 169 Japanese patients with type 2 diabetes mellitus with blood glucose levels that were inadequately controlled with diet and exercise therapy alone, or with diet and exercise therapy plus a sulfonylurea (SU) drug, we evaluated the safety and effi
Autor:
Toshiaki Hanafusa, Shigeru Kageyama, Kohei Kaku, Nigishi Hotta, Katsuhisa Ioriya, Ryuzo Kawamori
Publikováno v:
Journal of Diabetes Investigation
Aims/Introduction The aim of the present study was to evaluate the long-term efficacy and safety of adding repaglinide in patients with type 2 diabetes mellitus whose blood glucose levels were not sufficiently controlled by treatment with a dipeptidy
Autor:
Kiyoshi Kubota, Toshiaki Nakamura, Naoya Hatanaka, Kotonari Aoki, Mayumi Mochizuki, Akira Kokan, Hisashi Urushihara, Tatsuo Kagimura, Takeshi Hirakawa, Shigeru Kageyama, Daisuke Koide, Tsugumichi Sato, Ken Nakajima, Kou Miyakawa
Publikováno v:
Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku. 19:57-74
Autor:
Yasuhiko Kai, Shigeru Kageyama, Rei Maeda, Akira Kokan, Kou Miyakawa, Kiichiro Tsutani, Mikio Masada, Kiyoshi Kubota, Toshimichi Nishi
Publikováno v:
Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku. 17:55-66
Autor:
Kohei Kaku, Shigeru Kageyama, Toshiaki Hanafusa, Ryuzo Kawamori, Daisuke Kashiwabara, Nigishi Hotta
Publikováno v:
Journal of Diabetes Investigation. 3:302-308
Aims/Introduction: Repaglinide is a short-acting insulin secretagogue. We assessed the efficacy and safety of repaglinide in comparison with nateglinide in Japanese patients with type 2 diabetes previously treated with diet and exercise. Materials an
Autor:
Atsushi Utsuno, Shigeru Kageyama, Shigenori Kawasaki, Takeshi Kadokura, Itsuro Nagase, Satoshi Yoshida, Masako Saito, Kenichi Kazuta
Publikováno v:
Diabetology International. 2:172-182
This phase 1, randomized, placebo-controlled, dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ipragliflozin (ASP1941) in healthy Japanese subjects. Subjects received a single oral dose (1–300 mg)
Publikováno v:
Clinical and Experimental Hypertension. 33:133-140
The achievement rate of blood pressure (BP) target and the relationship between on-treatment BP and development of cardiovascular events (i.e., stroke, myocardial infarction, and heart failure) were investigated in a total of 8,897 patients in the Ja